Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00440388
Status:
COMPLETED
Last Update Posted:
2010-08-27
First Post:
2007-02-23
Brief Title:
Safety Efficacy Study of AT-101 in Combination w Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkins Lymphoma
Sponsor:
Ascenta Therapeutics
Organization:
Ascenta Therapeutics
Organization Data
Organization:
Ascenta Therapeutics
Class:
INDUSTRY
Study ID:
AT-101-CS-203
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ascenta Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Jeffrey Brill Associate Director Clinical Development
Old Organization:
Ascenta Therapeutics